Tibotec Pharmaceuticals, Ireland

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Tibotec Pharmaceuticals, Ireland sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).

16 total trials none currently recruiting 16 completed top decile by trial count

Tibotec Pharmaceuticals, Ireland: 16 sponsored US clinical trials, none currently recruiting.

Tibotec Pharmaceuticals, Ireland sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 16 completed. 7 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Human Immunodeficiency Virus - Type 1, with 1 trials.

Top-decile sponsor footprint

Tibotec Pharmaceuticals, Ireland ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

16 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

16 total, page 1 of 1

COMPLETED Phase 1

TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435

NCT01046058
COMPLETED Phase 2

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

NCT00980330
COMPLETED Phase 2

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

NCT00915655
COMPLETED Phase 2

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

NCT00882908
COMPLETED Phase 2

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

NCT00665847
COMPLETED Phase 3

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

NCT00543725
COMPLETED Phase 3

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

NCT00540449
COMPLETED Phase 3

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

NCT00524368
COMPLETED Phase 2

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

NCT00355524
COMPLETED Phase 3

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

NCT00359021
COMPLETED Phase 3

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

NCT00254046
COMPLETED Phase 3

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

NCT00258557
COMPLETED Phase 2

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

NCT00110305
COMPLETED Phase 3

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

NCT00110877
COMPLETED Phase 2

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

NCT00081588
COMPLETED Phase 2

TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

NCT00071097

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 8
Phase 3 7

Therapeutic Areas

Human Immunodeficiency Virus - Type 1 1
HIV-1 1
HIV Infections 1
HIV 1

How the Tibotec Pharmaceuticals, Ireland archive is shaped

16 indexed studies, none listed as recruiting (0% open); 16 completed (100%).

Phase mix: 7 late (III/IV) vs 9 early (I/II) (balanced across stages).

Top condition: Human Immunodeficiency Virus - Type 1 (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Tibotec Pharmaceuticals, Ireland: archived-pipeline peers nationwide

Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Tibotec Pharmaceuticals, Ireland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%5%10%15% Total trials Recruiting share Tibotec Pharmaceuticals, IrelandAccelerated Community Oncology Research NetworkAltimmuneAmerican UniversityAnthera Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Tibotec Pharmaceuticals, Ireland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Tibotec Pharmaceuticals, Ireland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 16 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Tibotec Pharmaceuticals, Ireland page

16 registered trials is a research-attention snapshot, not an endorsement of Tibotec Pharmaceuticals, Ireland or any single study.

  • None of Tibotec Pharmaceuticals, Ireland's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Human Immunodeficiency Virus - Type 1 is the condition Tibotec Pharmaceuticals, Ireland studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Human Immunodeficiency Virus - Type 1 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Tibotec Pharmaceuticals, Ireland pipeline card: 16 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.